MPH Health Care AG: Preliminary IFRS result 2019
- Net income for the year 11.08 million Euro, earnings per share 0.26 Euro (previous year 37.02 million Euro, earnings per share 0.86 Euro).
- The net asset value was Euro 6.34 per share (previous year Euro 6.29).
Berlin, 16 April 2020: MPH Health Care AG, Berlin (ISIN: DE000A0L1H32), announces its preliminary IFRS consolidated results for the 2019 financial year. In the 2019 financial year, the preliminary IFRS net profit for the year was EUR 11.08 million (EUR 0.26 earnings per share). The (preliminary) shareholders’ equity rose from Euro 269.13 million to Euro 271.64 million.
M1 Kliniken AG and CR Capital Real Estate AG, both listed on the Frankfurt Stock Exchange, continued their successful operations in fiscal 2019. At HAEMATO AG, which is also listed on the Frankfurt Stock Exchange, important measures to increase earnings and digitalisation were implemented in the past fiscal year.
M1 Kliniken AG performed fiscal year (previous year 190,000), thus further extending its market leadership. A key element to this is the further increase in the number of M1 specialist centres, which rose by 50% from 24 specialist centres (as of 31 December 2018) to 36 specialist centres as of 31 December 2019. Expansion abroad was also continued: Following the opening of the first M1 specialist centre in Vienna at the end of 2018, a total of 8 locations in Austria, Australia, the Netherlands and Switzerland were in operation at the end of 2019. The expansion of the product range to include aesthetic laser treatments (M1 laser) was also continued in 2019. Laser treatments are now offered at over 20 locations. The expansion will continue in the coming years with the target of operating a total of 100 specialist centres by the end of 2023.
M1 Kliniken AG was able to increase (preliminary) IFRS revenues by around 18 % to EUR 77.2 million and (preliminary) net income after taxes by around 47% to EUR 9.7 million. The (preliminary) equity capital has increased by around 7% to 68.2 million euros as of 31.12.2019. The M1 share price fell slightly from Euro 15,00 on December 31, 2018 to Euro 14.30 on December 31, 2019.
In the fiscal year 2019, CR Capital Real Estate AG was able to increase its (preliminary) IFRS net income to more than EUR 90 million (previous year: EUR 7.8 million), while the (preliminary) equity rose to approx. EUR 200 million (previous year: EUR 35.4 million). In order to set the course for future growth and the expansion of the business model towards a real estate investment house, accounting was changed to IFRS 10.
Following the share split, the share price of CR Capital Real Estate AG rose sharply from (converted) Euro 16.50 on December 31, 2018 to Euro 32.60 on December 31, 2019.
In the fiscal year 2019, HAEMATO AG generated (preliminary) IFRS consolidated sales revenues of Euro 197.8 million (previous year Euro 274.1 million), a balanced operating result (EBIT, previous year Euro 6.6 million) and a net loss for the year of Euro 1.2 million (previous year net income of Euro 6.3 million). With an equity ratio of 56.2 % (previous year 65.0 %), the company continues to be well positioned.
The share price of HAEMATO AG has decreased from 4.65 Euro on December 31, 2018 to 2.94 Euro on December 31, 2019. The measures and investments initiated in the business year 2019 to increase earnings and digitalization will probably take effect from 2020. The Management Board of HAEMATO AG continues to work on the optimization of its business processes and the approval of new products and product groups to broaden the portfolio.
“The development in 2020 currently depends largely on the further development of the Covid-19 pandemic. Therefore, no serious statements can be made at this time about the duration and consequences of this extraordinary, global crisis, which has hit almost every industry unexpected. However, we are confident that some of our investments will be able to take advantage of opportunities in this special situation, e.g. HAEMATO AG with the distribution of special drugs as well as M1 Kliniken AG, which can contribute to the diagnosis of the corona pandemic with its Europe-wide network of clinics and medical practices. MPH would also systematically benefit from this.
With regard to the distribution of a dividend for the financial year 2019, the Management Board and Supervisory Board will submit a suitable proposal in time for the Annual General Meeting,” said Patrick Brenske, MPH’s CEO. He added: “The current developments of our portfolio companies in the wake of the global turbulence on the stock markets as a result of the Covid-19 pandemic could possibly lead to some of our investments not paying a dividend for the past financial year in order to have sufficient financial reserves at their disposal. As soon as a return to “normal” business operations is achieved, MPH will – as in the past – allow its shareholders to participate in the company’s success accordingly”.
It is also planned to expand the portfolio this year and next year to include telemedicine and mail-order pharmacies. For this purpose, MPH Ventures GmbH has founded a mail-order pharmacy in the Netherlands within the “Ventures” division of MPH through one of its subsidiaries in the first quarter of 2020.